Grace Therapeutics, Inc.
6.4M
$36.36M
-2.88
$-0.79
No price alerts set. Add an alert to get notified!
-2.88
0.41
$-0.79
-14.36%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ABVC
ABVC BioPharma, Inc.
|
$1.14 | -3.39% | -3.35 | $16.52M | 0.31 |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
$1.31 | -6.43% | -1.21 | $41.10M | 0.22 |
|
CALC
CalciMedica, Inc.
|
$0.58 | -4.29% | -294.52 | $9.13M | -1.46 |
|
LTRN
Lantern Pharma Inc.
|
$2.31 | -13.81% | -1.47 | $26.00M | 0.01 |
|
LVTX
LAVA Therapeutics N.V.
|
$1.74 | -3.87% | -2.01 | $45.77M | 0.00 |
|
OKUR
OnKure Therapeutics, Inc.
|
$4.90 | -2.20% | -1.11 | $67.00M | 0.01 |
|
PDSB
PDS Biotechnology Corporation
|
$0.93 | -28.05% | -1.25 | $51.80M | 561.21 |
|
RNXT
RenovoRx, Inc.
|
$0.90 | -5.09% | -2.85 | $31.58M | 0.02 |
|
TVRD
Tvardi Therapeutics, Inc.
|
$3.01 | -6.81% | -2.07 | $28.24M | 0.01 |
|
XLO
Xilio Therapeutics, Inc.
|
$8.47 | -1.51% | -20.21 | $48.98M | 0.20 |
* Peer stocks are selected based on market capitalization and sector
$5.18
$1.79
$0.00
0.00%
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
